Biopharma and legal experts discuss at a recent summit the need for multi-stakeholder action to foster trust across the healthcare system. Capital is going to flow away from unethical organizations, one executive predicted.
Trust is a precious commodity and speakers at a recent summit in India deliberated the value of ethical conduct in the healthcare industry and the role of multi-stakeholder action to achieve “real and sustainable” change in the area.
Andrew Blasi, director at law firm Crowell & Moring, defined the importance of trust in the sector, where patients need...
Create an account to read this article
Already a subscriber?
One Phase III trial hits but a second study misses by a mile.
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
